Aspirin News and Research

RSS
Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Women need to be educated about the warning signs and symptoms of preeclampsia

Women need to be educated about the warning signs and symptoms of preeclampsia

Daily aspirin can reduce risk of colorectal cancer in adults

Daily aspirin can reduce risk of colorectal cancer in adults

Researchers discover novel therapeutic strategy for ischemic stroke using experimental model

Researchers discover novel therapeutic strategy for ischemic stroke using experimental model

Study examines sex differences in the cause of death after stroke

Study examines sex differences in the cause of death after stroke

High altitude experts explain pneumolysis caused by COVID-19

High altitude experts explain pneumolysis caused by COVID-19

Azithromycin trial fails to provide evidence of benefit in COVID-19

Azithromycin trial fails to provide evidence of benefit in COVID-19

Neutrophils may play a key role in COVID-19-related thrombosis

Neutrophils may play a key role in COVID-19-related thrombosis

Lipid storm in severe COVID-19 linked to high COX/LOX pathway activity

Lipid storm in severe COVID-19 linked to high COX/LOX pathway activity

Could beta-blockers be a potential treatment for COVID-19?

Could beta-blockers be a potential treatment for COVID-19?

International trialists receive prestigious award for research on low-dose aspirin

International trialists receive prestigious award for research on low-dose aspirin

UIC conducts three clinical trials to study blood clot prevention in COVID-19 patients

UIC conducts three clinical trials to study blood clot prevention in COVID-19 patients

Combination of ticagrelor and aspirin reduces subsequent stroke risk in patients with heart plaque

Combination of ticagrelor and aspirin reduces subsequent stroke risk in patients with heart plaque

Combination of polypill and aspirin can reduce cardiovascular events by up to 40%

Combination of polypill and aspirin can reduce cardiovascular events by up to 40%

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Potent antiplatelet drug not superior to standard of care in reducing heart attack risk during angioplasty

Polypill plus aspirin and polypill alone reduced cardiovascular disease risk

Polypill plus aspirin and polypill alone reduced cardiovascular disease risk

A promising vaccine for treating poorly immunogenic tumors

A promising vaccine for treating poorly immunogenic tumors

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

Aspirin to be tested as a potential COVID-19 treatment as part of RECOVERY trial

CAC scanning can help doctors decide which patients might benefit from aspirin therapy

CAC scanning can help doctors decide which patients might benefit from aspirin therapy

Aspirin use associated with reduced mortality risk in hospitalized COVID-19 patients

Aspirin use associated with reduced mortality risk in hospitalized COVID-19 patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.